Transferrin Inhibitors
2 drugsAbout Transferrin
Transferrin is a key protein responsible for iron transport throughout the body, maintaining iron homeostasis. It binds iron and delivers it to cells via receptor-mediated endocytosis.
Transferrin is a clinically relevant drug target for specific conditions related to iron imbalances. Currently, there is no genetic evidence data available linking Transferrin to specific diseases.
Transferrin is targeted by two FDA-approved small molecule drugs: IRON SUCROSE and MONOFERRIC, indicated for iron-related conditions. Novartis and PHARMACOSMOS are the key players in this space.
Top Transferrin Drugs
Novartis and PHARMACOSMOS are the only two companies with approved Transferrin-targeting drugs.
Low market concentration suggests opportunities for new entrants with innovative approaches.
Transferrin Drug Modality Landscape
Modalities
Routes of Administration
Transferrin is druggable by small molecules, though no oral formulations are currently approved.
Exploring alternative modalities like antibodies or peptides could provide differentiation.
Transferrin Clinical Trials 84 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Transferrin. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 10 | 7 | 1 | 2 | 88% |
| Phase 2 | 17 | 5 | 7 | 5 | 42% |
| Phase 3 | 27 | 17 | 2 | 8 | 89% |
| Phase 4 | 30 | 17 | 0 | 12 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
1 Phase 3 trial testing approved Transferrin drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting Transferrin. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
Transferrin Drug Approval Timeline (2020 - 2025)
The first drug was approved in 2020, with the most recent approval in 2025, spanning 6 years.
Recent approvals suggest renewed interest, but further growth may be limited by market saturation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 65 (13 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Transferrin. A trial counts if an approved drug acting on Transferrin is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.